Details of the Drug

General Information of Drug (ID: DM3TH6Y)

Drug Name
CBP-307
Synonyms CBP-307; CBP 307; CBP307; BCP20840; AKOS040748092
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C24H26FN3O3
Canonical SMILES
CC(C)CC1=CC=C(C=C1)C2=NC(=NO2)C3=CC(=C(C=C3)CNC4CC(C4)C(=O)O)F
InChI
InChI=1S/C24H26FN3O3/c1-14(2)9-15-3-5-16(6-4-15)23-27-22(28-31-23)17-7-8-18(21(25)12-17)13-26-20-10-19(11-20)24(29)30/h3-8,12,14,19-20,26H,9-11,13H2,1-2H3,(H,29,30)
InChIKey
JNFXMFRSTYONCX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
139266790
TTD ID
DLK93N

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04700449) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Connect Biopharma